二甲双胍联合同步放化疗治疗局部晚期非小细胞肺癌的NRG-LU001二期随机临床试验
NRG-LU001是一项开放标签、二期国际多中心随机试验,入组无糖尿病的不可切除III期NSCLC患者,比较同步放化疗联合或不联合二甲双胍的疗效。加用二甲双胍耐受性良好但未改善生存。
要点
- 两组1年总生存接近(80.8% vs 80.2%),局部区域复发与远处转移无显著差异。
- 二甲双胍联合治疗耐受性良好,不良事件与对照组无显著差异。
核心结论
- 在无糖尿病的不可切除III期NSCLC患者中,同步放化疗加用二甲双胍耐受性良好,但未改善生存。
研究设计与样本
- 入组无糖尿病的不可切除III期NSCLC患者,按体能状态、组织学与分期分层,意向性治疗分析。
- 共入组170例,排除后167例可评估(中位年龄64岁;男97例,58.1%;白人137例,82.0%),对照组81例、二甲双胍组86例。
主要发现
- 1年总生存率对照组80.2%(95%CI 69.3%-87.6%),二甲双胍组80.8%(95%CI 70.2%-87.9%)。
- 1年与2年局部区域复发及远处转移无显著差异,两组不良事件无显著差异。
- 存活患者中位随访27.7个月(范围0.03-47.21个月)。
关键数值与推荐
- 主要终点设计为检测1年PFS从50%提高至65%(15%改善,HR 0.622)。
- 毒性按CTCAE 4.03版评价。
临床怎么用
- 结果不支持在不可切除III期NSCLC的同步放化疗中常规加用二甲双胍以改善生存。
- 临床分期仍是该人群中与PFS相关的重要因素,分层与预后评估应重视分期。
局限性
- 为二期开放标签研究,样本量有限(167例可评估),统计效能受预设效应量限制。
- 仅纳入无糖尿病患者,结论不能外推至合并糖尿病的NSCLC人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Non-small cell lung cancer (NSCLC) has relatively poor outcomes. Metformin has significant data supporting its use as an antineoplastic agent. OBJECTIVE: To compare chemoradiation alone vs chemoradiation and metformin in stage III NSCLC. DESIGN, SETTING, AND PARTICIPANTS: The NRG-LU001 randomized clinical trial was an open-label, phase 2 study conducted from August 24, 2014, to December 15, 2016. Patients without diabetes who were diagnosed with unresectable stage III NSCLC were stratified by performance status, histology, and stage. The setting was international and multi-institutional. This study examined prespecified endpoints, and data were analyzed on an intent-to-treat basis. Data were analyzed from February 25, 2019, to March 6, 2020. INTERVENTIONS: Chemoradiation and consolidation chemotherapy with or without metformin. MAIN OUTCOMES AND MEASURES: The primary outcome was 1-year progression-free survival (PFS), designed to detect 15% improvement in 1-year PFS from 50% to 65% (hazard ratio [HR], 0.622). Secondary end points included overall survival, time to local-regional recurrence, time to distant metastasis, and toxicity per Common Terminology Criteria for Adverse Events, version 4.03. RESULTS: A total of 170 patients were enrolled, with 167 eligible patients analyzed after exclusions (median age, 64 years [interquartile range, 58-72 years]; 97 men [58.1%]; 137 White patients [82.0%]), with 81 in the control group and 86 in the metformin group. Median follow-up was 27.7 months (range, 0.03-47.21 months) among living patients. One-year PFS rates were 60.4% (95% CI, 48.5%-70.4%) in the control group and 51.3% (95% CI, 39.8%-61.7%) in the metformin group (HR, 1.15; 95% CI, 0.77-1.73; P = .24). Clinical stage was the only factor significantly associated with PFS on multivariable analysis (HR, 1.79; 95% CI, 1.19-2.69; P = .005). One-year overall survival was 80.2% (95% CI, 69.3%-87.6%) in the control group and 80.8% (95% CI, 70.2%-87.9%) in the metformin group. There were no significant differences in local-regional recurrence or distant metastasis at 1 or 2 years. No significant difference in adverse events was observed between treatment groups. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the addition of metformin to concurrent chemoradiation was well tolerated but did not improve survival among patients with unresectable stage III NSCLC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02186847.
引用
- Skinner H, Hu C, Tsakiridis T, et al. Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 34323922. doi:10.1001/jamaoncol.2021.2318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。